The RAS association domain family 1A (RASSF1A) aberrant methylation in blood has been confirmed for use as a diagnostic and prognostic biomarker for HCC-afflicted patients [12,13,14,15,16,17]. This evidence concerns the gene RASSF1 and hepatocellular carcinoma.